Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Emily Tyler

Pain Medicine Phoenix, AZ Nurse Practitioner

NPI 1548632623 CMS profile 10958411

3811 E Bell Rd, Ste 160, Phoenix, AZ 85032

Open in the dashboard

General payments

$3,960

81 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Emily Tyler of Phoenix, AZ is reported in the CMS Open Payments database as having received $3,960 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $115 1
2023 General $104 6
2022 General $2,033 34
2021 General $1,709 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Tyler
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Emily Tyler were reported at $0. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Emily Tyler Pain Medicine median Middle half National median
2019 $0 $506 $144–$1,566 $163
2020 $0 $315 $96–$934 $114
2021 $1,709 $452 $134–$1,237 $132
2022 $2,033 $475 $124–$1,407 $149
2023 $104 $480 $136–$1,384 $160
2024 $115 $521 $164–$1,511 $164
2025 $0 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Spinal Simplicity, LLC $1,188 9 payments
  2. Medtronic, Inc. $1,032 15 payments
  3. Abbott Laboratories $693 22 payments
  4. Boston Scientific Corporation $670 27 payments
  5. Stimwave Technologies Incorporated $133 1 payment
  6. Vertos Medical, Inc. $115 1 payment
  7. TerSera Therapeutics LLC $59 2 payments
  8. AbbVie, Inc. $29 1 payment
  9. Scilex Pharmaceuticals Inc. $17 1 payment
  10. Ethicon US, LLC $14 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $2,561 72 payments
  2. Travel and Lodging $1,327 7 payments
  3. Education $72 2 payments
Products named General payments · program years 2021–2024
  1. HA MINUTEMAN G3-R $1,188 9 payments
  2. INTELLIS $765 10 payments
  3. Proclaim IPG $258 7 payments
  4. PROCLAIM Neuromodulation $243 12 payments
  5. Entrada $185 3 payments
  6. SYNCHROMED $178 2 payments
  7. PROCLAIM Neuromodulation $145 1 payment
  8. StimQ Receiver Stimulator Kit Channel A US w Receiver $133 1 payment
  9. StimQ Freedom 4A Receiver Kit Channel A US Receiver $133 1 payment
  10. StimQ Freedom 8A Receiver Kit Channel A US w Receiver $133 1 payment
  11. Other $1,129 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

752

Median for Nurse Practitioner: 389

Drug cost

$25,589

Median for Nurse Practitioner: $21,885

Branded share of claims

35.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 281 $7,199
Oxycontin Oxycodone Hcl Brand 22 $5,159
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 110 $3,204
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 76 $2,506
Morphine Sulfate Er Morphine Sulfate Brand 60 $2,057
Pregabalin Generic 50 $1,569
Tramadol Hcl Generic 54 $1,235
Hydromorphone Hcl Generic 32 $993
Gabapentin Generic 26 $803
Morphine Sulfate Generic 30 $678

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$187,502

Medicare's payments for the services billed

Medicare patients

645

Average age 77

Services billed

2,678

405 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Depression 62%
Ischemic heart disease 52%
Diabetes 50%
Chronic kidney disease 50%
Heart failure 40%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record